Education
About Us
Working with TipRanks
Follow Us
FMED - ETF AI Analysis
Top Page
Fidelity Disruptive Medicine ETF (FMED)
Rating:60Neutral
Price Target:―
Positive Factors
Recent Performance Momentum
The ETF has shown positive performance over the past month, three months, and year-to-date, indicating recent upward momentum.
Focused Exposure to Disruptive Healthcare
With the vast majority of assets in the health care sector, the fund gives targeted access to companies working on innovative medical technologies and treatments.
Presence of Strong Recent Winners in Top Holdings
Some of the larger positions, such as Cogent Biosciences and Penumbra, have delivered strong gains this year, helping support the fund’s overall results.
Negative Factors
High Sector Concentration
Over 90% of the portfolio is in health care, so the fund is heavily exposed to swings in that single sector.
Heavy U.S. Market Dependence
The ETF is overwhelmingly invested in U.S. companies, offering limited geographic diversification.
Mixed Performance Among Top Holdings
Several key holdings, including Boston Scientific, Argenx, Veeva Systems, Alnylam Pharma, and Intuitive Surgical, have shown weak or negative performance this year, which can drag on returns.
FMED vs. SPDR S&P 500 ETF (SPY)
AUM56.68M
RegionGlobal
Expense Ratio0.50%
Beta0.84
IssuerFidelity
Inception DateJun 12, 2023
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume10,522
30 Day Avg. Volume7,236
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
37.16Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering66
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FMED Summary
The Fidelity Disruptive Medicine ETF (FMED) focuses on innovative healthcare companies working on new treatments, medical devices, and health technologies instead of tracking a traditional market index. It invests mainly in U.S. health care and related tech firms involved in areas like biotechnology, digital health, and precision medicine. Well-known holdings include Boston Scientific and Danaher. Someone might consider FMED if they want growth potential from medical breakthroughs and a way to invest in the future of healthcare. A key risk is that it is heavily concentrated in healthcare and can rise or fall sharply with that sector.
How much will it cost me?The Fidelity Disruptive Medicine ETF (FMED) has an expense ratio of 0.50%, which means you’ll pay $5 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on innovative healthcare companies that require more research and expertise to select.
What would affect this ETF?The Fidelity Disruptive Medicine ETF (FMED) could benefit from ongoing advancements in biotechnology, genomics, and digital health, as well as increased global demand for innovative healthcare solutions. However, it may face challenges from regulatory changes, high research and development costs, and potential market volatility in the healthcare sector. Its global exposure and focus on disruptive medicine make it sensitive to both breakthroughs and setbacks in medical innovation.
FMED Top 10 Holdings
FMED is a pure play on disruptive healthcare, with nearly all its firepower in medical and biotech names around the globe. Argenx is one of the few bright spots, quietly rising on the back of a promising drug pipeline, while Cogent Biosciences remains a problem child, dragging on returns as its losses and weak trading trend weigh on the fund. Heavyweights like Danaher and Intuitive Surgical look more mixed, with solid businesses but softer stock momentum, and names like Boston Scientific and Veeva have been lagging, leaving the ETF leaning on future innovation rather than recent market strength.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ― | 4.17% | $2.44M | ― | ― | ― | |
| Danaher | 4.10% | $2.40M | $131.71B | -8.74% | 75 Outperform | |
| Boston Scientific | 3.82% | $2.23M | $101.72B | -28.12% | 79 Outperform | |
| Argenx Se | 3.81% | $2.22M | $43.90B | 21.96% | 79 Outperform | |
| Cogent Biosciences | 3.71% | $2.16M | $5.73B | 384.64% | 37 Underperform | |
| Intuitive Surgical | 3.38% | $1.97M | $170.20B | 0.52% | 78 Outperform | |
| Alnylam Pharma | 3.33% | $1.94M | $42.07B | 31.22% | 60 Neutral | |
| Veeva Systems | 3.20% | $1.87M | $29.72B | -20.64% | 66 Neutral | |
| Moderna | 2.80% | $1.64M | $21.09B | 55.66% | 59 Neutral | |
| Insulet | 2.61% | $1.52M | $16.62B | -3.51% | 70 Outperform |
FMED Technical Analysis
Negative
―
Price Trends
26.46
Negative
26.85
Negative
25.55
Negative
Market Momentum
-0.49
Positive
28.39
Positive
7.11
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FMED, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 25.64, equal to the 50-day MA of 26.46, and equal to the 200-day MA of 25.55, indicating a bearish trend. The MACD of -0.49 indicates Positive momentum. The RSI at 28.39 is Positive, neither overbought nor oversold. The STOCH value of 7.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FMED.
FMED Peer Comparison
Comparison Results
Performance Comparison
FMED
Fidelity Disruptive Medicine ETF
24.06
-0.36
-1.47%
MEDI
Harbor Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
BMED
Future Health ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents